個(gè)人簡(jiǎn)介：
Dr Zhang has over 20 years of experience in both academic and commercial drug discovery establishments. His past roles include joint head of the biochemistry division of a multi-disciplinary academic drug discovery initiative at the Royal London Hospital. He was jointly responsible for a team of biochemists in studying the role of reperfusion injury and drug discovery in inflammatory diseases. In 1998 he became the head of a European pharmaceutical drug discovery establishment of Teijin Pharma, Japan. He focused on identifying and validating novel drugable targets in the fields of kidney and pulmonary fibrosis and COPD. He also helped Teijin Pharma to build up an extensive collaboration network in the UK.Since 2008 he has been working as the Business Development Executive for Asia/Pacific in MRC Technology. He is responsible for identifying and evaluating new business opportunities and for forging partnership deals with Pharma/Biotech companies in the Asia and Pacific region. He leads the MRCT initiative to penetrate China’s emerging economic powerhouse by helping build up a far-reaching network of useful contacts in China. He is responsible for the establishment of several high profile strategic collaborations between MRCT and top-tier research institutions in the Chinese Academy of Sciences.Dr Zhang has a wealth of experience and finely honed strategies in assessing and leveraging collaboration opportunities in research, technology transfer and RD development. He brought the first non-MRC drug target for fibrosis to MRCT discovery centre, which resulted in a successful multi-million pound deal with UCB in 2013. In 2014 he successfully led two multi-million pound out-licensing negotiations and deals to China.Dr Zhang has an excellent knowledge of the inner workings of both the West and China at the national and regional levels. He also has excellent bilingual and bicultural communication skills and an ability to sensitively source business intelligence to diplomatically handle the complexities that arise in building international collaborations.
公司簡(jiǎn)介：
MRC(英國國家醫學(xué)研究院，Medical Research Council)成立于1913年，是英國政府性醫學(xué)研究機構。 在過(guò)去的100多年中，MRC在國際醫藥領(lǐng)域取得了令人矚目的成就，其中包括發(fā)現DNA雙螺旋結構、單克隆抗體技術(shù)等重大成果，先后有29位科學(xué)家在MRC完成的成果獲得諾貝爾獎。MRCT(Medical Research Council Technology)是MRC負責知識成果轉化的機構，致力于將前沿科學(xué)研究發(fā)現轉化為商業(yè)產(chǎn)品。MRCT的工作包括掌控和管理MRC的全部知識產(chǎn)權和技術(shù)轉讓?zhuān)灾鏖_(kāi)發(fā)擁有獨家知識產(chǎn)權的新藥和技術(shù)，與制藥公司共同進(jìn)行后期開(kāi)發(fā)等。MRCT目前已經(jīng)與百健艾迪、羅氏、武田、默沙東等公司成功開(kāi)發(fā)了藥物上市。近期，MRCT還與優(yōu)時(shí)比、輝瑞、阿斯利康、中科院上海細胞生物所、中科院生物物理所等企業(yè)機構在小分子、抗體藥物等方面進(jìn)行了合作。